Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|3|356-363

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.3, 2018-02, pp. : 356-363

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 485-493

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevalence of Epstein–Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 10, 2013-11 ,pp. : 1248-1254

John Wiley & Sons Inc

Access to resources Recommend Favorite

Falls by individuals with chronic obstructive pulmonary disease: A preliminary 12‐month prospective cohort study

By  

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. 7, 2015-10 ,pp. : 1096-1101

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite